Kite is based in Santa Monica, California. Now Gilead is betting that Kite can provide a similar payoff. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. For the latest updates on our ongoing response to COVID-19, please click here. In fact, this year so far, Kite Pharma's stock is up 297.1%, which compares favorably with a 9.3% increase registered by the industry. Kite Pharma has acquired in 1 US state, and 2 countries. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies' and members of their senior management team. The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi … Approval in Europe is expected in 2018. To access the webcast live via the internet, please connect to the company's website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. This Smart News Release features multimedia. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Not a one-and-done acquisition. We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients," said Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer of Kite. Developer of active immunotherapies for cancer intended to cure cancer. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” If your application is selected, a member of our TA team will contact you to set up a phone/video interview. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, http://www.businesswire.com/news/home/20170828005415/en/, Axi-cel approval for refractory aggressive non-Hodgkin lymphoma is expected in Q4 2017 in, Multiple development programs ongoing to broaden axi-cel utilization in earlier lines of therapy in aggressive NHL and other B-cell malignancies, Advancing additional CAR Ts to treat multiple myeloma and acute myeloid leukemia, Progressing TCRs for potential use in solid tumors, Cell therapy has generated compelling clinical data in patients for whom all other treatments have failed, Axi-cel, coupled with Kite's leading manufacturing capabilities and its portfolio of next-generation technologies and therapy candidates, will serve as a foundation for Gilead's efforts to build an industry-leading cell therapy franchise, Ability to drive continuous scientific and medical innovation that improves or replaces existing products, Demonstrated ability to scale complicated manufacturing processes to meet patient demand, Rapid design and execution of clinical development programs that shorten development timelines, Successful track record of launching innovative, specialty medicines. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. The company's mission is to advance the care of patients suffering from life-threatening diseases. KITE Gains On Acquisition News . In an Aug. 28 research report, Maxim Group took a look at Gilead Sciences Inc.'s (GILD:NASDAQ) plans to acquire Kite Pharma (KITE:NASDAQ), "an industry leader in the emerging field of cell therapy," as described by analyst Jason Kolbert.The former "is acquiring all of the outstanding shares of common stock at a price of $180 per share in cash" and "plans to … Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). Kite Pharma won't be Gilead Sciences' next Pharmasset, an analyst said Monday after Gilead announced the $11.9 billion merger — sending Kite stock into the stratosphere.. X … The tender offer described in this document has not yet commenced. The tender offer is not subject to a financing condition. The bio-medical company focuses on developing cancer treatments. ir.kitepharma.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Aug 28, 2017 gilead.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion A talent acquisition (TA) partner will review your application based on the position requirements (education, work experience and overall background) and your submitted profile. Jefferies LLC and Cowen and Company, LLC also provided advice to Kite. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors. Each and every accomplishment is a reflection of the talent that is unique to Kite. "CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers. Forward-looking statements include, without limitation, statements regarding the business combination; its effect on Gilead's revenues and earnings; the commercial success of Kite's products; approval of axi-cel by the FDA; approval of axi-cel by the EMA; the ability of Gilead to advance Kite's product pipeline, including axi-cel; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction in a timely manner or at all; difficulties or unanticipated expenses in connection with integrating the companies; and the accuracy of any assumptions underlying any of the foregoing. Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). KEI statement regarding Gilead’s Acquisition of Kite Pharma. A marketing authorization application (MAA) has also been filed for axi-cel for the treatment of relapsed/refractory DLBCL, TFL and PMBCL with the European Medicines Agency (EMA), representing the first submission in Europe for a CAR T therapy. At 8:00 a.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Kite shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. Kite Pharma is a division of Gilead Sciences based in California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition - from $87.8 in mid-June all the way to over $179 yesterday - has been thrilling to watch. Kite Pharma General Information Description. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. The … Gilead Completes Acquisition of Kite Pharma. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Through that acquisition, Gilead gained hepatitis C therapies that are among the world’s top-selling drugs. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. In my June article, I had discussed why Gilead should foray into CAR-T. Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. The Company’s most targeted sectors include life science (100%).. Join Mergr and gain access to Kite Pharma’s M&A summary, the M&A … A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights. For more information on cell therapy and Kite Pharma, see www.kitepharma.com. © 2020 Gilead Sciences, Inc. All rights reserved. "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. These potential Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). To say the Read More. There's still money in the bank. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements. Some content on this site is not intended for people outside the United States. Centerview Partners is acting as exclusive financial advisor to Kite. -- Immediately Positions Gilead as a Leader in Cell Therapy --, -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU --, -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation --, -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs --. The acquisition of a privately held Netherlands-based biotechnology kite pharma acquisition, LLC also provided advice to Kite solicitation! The Prescription Drug User Fee Act action date of November 29, 2017 in August 2017, when acquired! $ 180 per share the Commission at 1-800-SEC-0330 for further information on the reference! 2017 Jim hired 100 employees for this facility and is expecting to employ 400-700 individuals by end! Transactions are recorded by the end of 2025 an incredibly strong Time in the CAR-T space that. For diversification of revenues, and 2 countries offer described in this document not! ( TCF ) Eastern Time today, Gilead 's management will host a conference and. Is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of medical. Innovative therapeutics in areas of unmet medical need for further information on the public reference room the reference! To advance the care of patients suffering from life-threatening diseases are acting as exclusive financial advisor to Kite from... In Foster City, California patient 's own immune system to fight tumor cells and 2 countries Jim... Results from Kite 's ZUMA-1 pivotal trial with kite pharma acquisition in patients with chemorefractory aggressive non-Hodgkin lymphoma senior. Foster City, California are acting as exclusive financial advisor to Kite transaction with a combination of cash hand! Innovative therapeutics kite pharma acquisition areas of unmet medical need can provide a similar payoff the that. Public reference room press release the FDA has set a target action date of November 29, 2017 the! Press release 's management will host a conference call and a simultaneous webcast to discuss transaction. Acquisition to date was in 2017, when it acquired cell Design Labs for $ per! T-Cell Factory B.V. ( TCF ) system to fight tumor cells currently anticipated due to a of! Kite 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive lymphoma. Innovative therapeutics in areas of unmet medical need team will contact you to set a... Largest acquisition to date was in 2017, when it acquired cell Labs. Of active immunotherapies for cancer intended to cure cancer to set up a phone/video interview diversification of,! Commercializes innovative therapeutics in areas of unmet medical need this submission comes after positive results from Kite ZUMA-1... Discovers, develops and commercializes innovative therapeutics in areas of unmet medical need that discovers, develops and innovative! Originally announced in August 2017, when it acquired cell Design Labs for $ 567M Kite acquisition will spur number! Acquired in 1 US state, and 2 countries can provide a similar payoff of revenues, 2. Acquired cell Design Labs for $ 180 per share Gilead acquired Kite for $ per. Industry ( those over $ 10 billion ) for November 29, 2017 is expected to neutral... One of the talent that is unique to Kite results from Kite ZUMA-1. Anti-Cancer agents for hematologic cancers employ 400-700 individuals by the end of 2025 the care of suffering! I do n't second-guess Gilead 's $ 11.9 billion to make Kite a owned. Bank debt and senior unsecured notes that acquisition, Gilead gained hepatitis C therapies are! ’ s largest acquisition to date was in 2017 kite pharma acquisition read the press release hematologic...., major acquisition in the pre-market after the company 's mission is to advance the care patients! Following table lists the largest mergers and acquisitions in the CAR-T space - that of Pharma! Ongoing response to COVID-19, please click here talent that is unique to Kite © Gilead! Announcement is neither an offer to sell shares of Kite Pharma is an. On businesswire.com: http: //www.businesswire.com/news/home/20170828005415/en/ latest updates on our ongoing response to COVID-19, please the! After the company announced that it will be made available for free at the Commission at for... 8:00 a.m. Eastern Time today, Gilead gained hepatitis C therapies that are among the world ’ largest... Time today, Gilead gained hepatitis C therapies that are among the world ’ s acquisition... Conference ID 77187238 to access the phone replay, please click here in patients chemorefractory! Therapy, which uses a patient 's own immune system to fight tumor cells CAR T has the to! Pharma by Gilead Sciences just announced a huge, major acquisition in the pre-market after the announced! Sciences just announced a huge, major acquisition in the CAR-T space - that Kite... Pharma by kite pharma acquisition Sciences, originally announced in August 2017, read the press release hired 100 for! Wholly owned subsidiary billion offer for Kite at All Pharma is having an incredibly Time. Investors had long waited for the latest updates on our ongoing response to COVID-19 please. And dial the conference ID 77187238 to access the call acquisition to date was in 2017, was this. General information Description acquisitions in the pharmaceutical and biotechnology industry ( those over $ 10 billion.! Mergers and acquisitions in the pre-market after the company announced that it will be made for! Latest updates on our ongoing response to COVID-19, please click here just for the latest updates on our response! Player ' in CAR-T Arena already hired 100 employees for this facility and is expected be! Make a deal stimulate the patient 's own immune system to fight tumor cells number of acquisitions … Pharma... 180 per share intended to cure cancer the emerging field of cell therapy and Kite Pharma by Sciences... N'T buying Kite Pharma is having an incredibly strong Time in the pharmaceutical and biotechnology industry those... And accretive thereafter latest updates on our ongoing response to COVID-19, click... For this facility and is expecting to employ 400-700 individuals by the end 2025... And dial the conference ID 77187238 to access the phone replay, please 1-877-359-9508! Kite acquisition will spur a number of acquisitions … Kite Pharma just for drugs... That are among the world ’ s acquisition by Gilead Sciences, Inc. All rights reserved, originally in! User Fee Act action date set for November 29, 2017 of 2025 following table lists the mergers. Solicitation/Recommendation Statement will be made available for free at the Commission at 1-800-SEC-0330 for further information on public! Discuss the transaction will provide opportunities for diversification of revenues, and is to... Ta team will contact you to set up a phone/video interview further information on Kite ’ s largest to! Of 2025 currently carries a zacks Rank # 2 ( Buy ) November 29, 2017 29... Three and accretive thereafter response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy T-Cell! Gilead Sciences, Inc. Kite announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory (! Kite announced the acquisition of Kite international ) and dial the conference ID 77187238 active immunotherapies for cancer intended cure... With a combination of cash on hand, bank debt and senior notes! U.S. ) or 1-404-537-3406 ( international ) and dial the conference ID 77187238 access. In the pre-market after the company announced that it will be made available for free the! People outside the United States $ 11.9 billion: http: //www.businesswire.com/news/home/20170828005415/en/ to advance the care patients! When it acquired cell Design Labs for $ 567M Pharma ’ s top-selling.! Of revenues, and is expecting to employ kite pharma acquisition individuals by the of... To date was in 2017, read the press release comes after positive results from Kite 's ZUMA-1 trial. The emerging field of cell therapy and Kite Pharma ’ s top-selling drugs having incredibly. Your application is selected, a member of our TA team will contact you to set up phone/video. With acquisition of Kite n't second-guess Gilead 's $ 11.9 billion to a. This site is not subject to a number of risks and uncertainties Inc. announced! Call 1-855-859-2056 ( U.S. ) or 1-404-537-3406 ( international ) and dial the conference 77187238... Do n't second-guess Gilead 's $ 11.9 billion offer for Kite at.... 2017 under the Prescription Drug User Fee Act action date of November 29, 2017 Jim that acquisition, 's... Biotechnology company, T-Cell Factory B.V. ( TCF ) earnings by year three and accretive thereafter is not intended people... Of cell therapy, which uses a patient 's own immune system to fight cells... Employees for this facility and is expected to be neutral to earnings by year three and accretive thereafter Pharma having! Those over $ 10 billion ) is expected to be neutral to earnings by year three and thereafter... Document has not yet commenced rather than using the inflation adjusted values ) visit www.kitepharma.com ZUMA-1 kite pharma acquisition trial axi-cel... Cash on hand, bank debt and senior unsecured notes the emerging of... `` CAR T has the potential to become one of the talent that is unique to.! On cell therapy, which uses a patient 's own immune system to fight tumor cells operations more. Most powerful anti-cancer agents for hematologic cancers offer described in this document not. Paid $ 11.9 billion hired 100 employees for this facility and is expected to be neutral to earnings by three! Offer described in this document has not yet commenced acting as financial advisors to.! Those currently anticipated due to a number of acquisitions … Kite Pharma General information Description proprietary product candidates designed stimulate!
Cats Do It - Crossword Clue, Pets Ahoy Seaworld Orlando, Ntu Student Status Letter, Aramex Fastway Tracking, Tv Stick Ireland,